Clinical trials: Advanced Malignant Solid Tumors
Malignant Ascites Caused by Advanced Solid Tumors
A Clinical Study of GK02 in Malignant Ascites
A single-arm, single-center, open-label clinical study comprising three cohorts, evaluating the safety, preliminary efficacy, and pharmacokinetic/ pharmacodynamic (PK/PD) characteristics of autologous tumor-reactive T cells…
- Trial name
- NCT07378436
- Testing
- GK02
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Beijing Geekgene Technology Co., LTD
Malignant Solid Tumor, Lymphoma
A Phase I, Open-Label, Multiple Ascending Dose Study of RRx-001 and Nivolumab
This is a dose escalation protocol to determine the feasibility of co-administration of RRx-001 and nivolumab. Immune surveillance is an endogenous mechanism to cause remission of neoplastic growth.
- Trial name
- PRIMETIME (NCT02518958)
- Testing
- RRx-001, Nivolumab
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- EpicentRx, Inc.
Solid Tumors, Hepatocellular Carcinoma (HCC)
A Phase I, First in Human Study of CBA-1205, Anti-DLK1 Monoclonal Antibody in Patients With Advanced Solid Tumors, Hepatocellular Carcinoma (HCC), Melanoma, and Pediatric Cancer
In this first-in-human, muticenter, non-randomized, open-label, standard 3+3 dose escalation Phase I study encompasses 5 parts (Part 1-5).
- Conditions
- Solid Tumors, Hepatocellular Carcinoma (HCC), Malignant Melanoma, Pediatric Cancer
- Trial name
- NCT06636435
- Testing
- CBA-1205 Part 1, CBA-1205 Part 2, CBA-1205 Part 3
- Where
- 5 sites in Japan
- Volunteers
- 66 people
- Sponsor
- Chiome Bioscience Inc.
Hematologic Tumors
Pharmacokinetic (PK) Study of Homoharringtonine (Omacetaxine Mepesuccinate) Administered Subcutaneously to Patients With Advanced Solid and Hematologic Tumors
PK Study of Homoharringtonine (Omacetaxine Mepesuccinate) Administered Subcutaneously to Patients With Advanced Solid and Hematologic Tumors
- Trial name
- NCT00675350
- Testing
- Omacetaxine
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- ChemGenex Pharmaceuticals
Tumor
Study of PXD101 Alone and in Combination With 5-Fluorouracil (5-FU) in Patients With Advanced Solid Tumors
This is a study to assess the combination of PXD101 and 5-Fluorouracil (5-FU)in patients with advanced solid tumors. The primary goal of the study is to understand the safety, anti-tumor activity, and how the study drug behaves…
- Trial name
- NCT00413322
- Testing
- belinostat, 5-Fluorouracil (5-FU)
- Where
- 3 sites in United States
- Volunteers
- 35 people
- Sponsor
- Valerio Therapeutics
Malignant Pleural Effusion, Malignant Pleural Mesothelioma
Study of RSO-021 in Patients With Malignant Pleural Effusion Due to Advanced/Metastatic Solid Tumors Including Mesothelioma
This is an open-label, non-randomized, multicenter, translational Phase 1/2 dose-escalation and expansion study designed to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor…
- Conditions
- Malignant Pleural Effusion, Malignant Pleural Mesothelioma, Mesothelioma, Mesotheliomas Pleural
- Trial name
- NCT05278975
- Testing
- RSO-021
- Where
- 10 sites in United Kingdom
- Volunteers
- 50 people
- Sponsor
- RS Oncology LLC
Neoplasms, Malignant
Phase I Study of MK-1496 in Patients With Advanced Solid Tumor (MK-1496-002 AM 4)(COMPLETED)
This study determines recommended clinical dose, to evaluate the safety, tolerability and pharmacokinetics of MK-1496 in patients with locally advanced and/or metastatic solid tumors who have failed standard therapy or for whom…
- Trial name
- NCT00880568
- Testing
- MK-1496
- Volunteers
- 27 people
- Sponsor
- Merck Sharp & Dohme LLC
Breast Cancer, Colorectal Cancer
Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies
This is a phase I/II, non randomized, open-label, dose escalation study to investigate the safety, tolerability and preliminary efficacy of CB-103.
- Conditions
- Breast Cancer, Colorectal Cancer, Adenoid Cystic Carcinoma, Non-hodgkin Lymphoma
- Trial name
- NCT03422679
- Testing
- CB-103
- Where
- 17 sites in United States, France and 4 more
- Volunteers
- 79 people
- Sponsor
- Cellestia Biotech AG
Malignancies, Solid Malignant Tumor
JL19001 Injection Alone or in Combination With Standard Therapy in Patients With Advanced Solid Tumors or Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
This is a Phase I, multicenter, single-arm, open-label clinical study designed to evaluate the safety and tolerability of JL19001 Injection as monotherapy (Phase Ia) or in combination with standard therapy (Phase Ib) in patients…
- Conditions
- Malignancies, Solid Malignant Tumor, NHL (Non-Hodgkin Lymphoma), Solid Tumor Cancer
- Trial name
- NCT07603479
- Testing
- JL19001, subcutaneous injection, 1 μg/kg, JL19001, subcutaneous injection, 5 μg/kg, JL19001, subcutaneous injection,10 μg/kg
- Where
- China
- Volunteers
- 14 people
- Sponsor
- Jecho Biopharmaceuticals Co., Ltd.
Cancer
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
This is a phase III, randomized, double-blind, placebo-controlled, multicenter study of the clinical response to fentanyl sublingual spray as a treatment for breakthrough cancer pain.
- Trial name
- NCT00538850
- Testing
- Fentanyl sublingual spray
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- INSYS Therapeutics Inc
Neoplasms, Malignant
Dose-Escalation, Safety, Pharmacokinetics Study of Cabazitaxel With Gemcitabine In Patients With Solid Tumor
Primary Objectives: Study part 1: To determine the Maximum Tolerated Dose (MTD) and the Dose Limiting Toxicities (DLTs) of cabazitaxel administered as a 1-hour infusion in combination with gemcitabine, every 3 weeks in patients…
- Trial name
- NCT01001221
- Testing
- cabazitaxel, gemcitabine
- Where
- 4 sites in United States
- Volunteers
- 19 people
- Sponsor
- Sanofi
Neoplasms
A Study Of PF-00299804 In Patients In Japan With Advanced Malignant Solid Tumors
To evaluate safety and tolerability of PF-00299804 in Japanese patients with advanced malignant solid tumors at doses up to the clinically recommended phase 2 dose in non-Japanese studies.
- Trial name
- NCT00783328
- Testing
- PF-00299804
- Where
- Japan
- Volunteers
- 13 people
- Sponsor
- Pfizer
Solid Tumors
A I/II Phase Clinical Study to Evaluate the Safety and Efficacy of RC288 in the Treatment of Solid Tumors
The primary objective is to evaluate the safety and tolerability of RC288; determine the maximum tolerated dose (MTD) and/or maximum administered dose (MAD) of RC288; and determine the recommended phase 2 dose (RP2D), and assess…
- Trial name
- NCT07537881
- Testing
- RC288 For Injection
- Where
- 14 sites in China
- Volunteers
- 326 people
- Sponsor
- RemeGen Co., Ltd.
Advanced Solid Tumors, Malignant Neoplasm
A Clinical Trial of MK-2750 in Participants With Advanced Solid Tumors (MK-2750-002)
MK-2750 is a trial medicine designed to treat certain solid tumors. MK-2750 is a type of treatment called an antibody drug conjugate (ADC). ADCs attach to a protein on cancer cells and deliver medicine to destroy those cells.
- Trial name
- NCT07876128
- Testing
- MK-2750, 5-HT3 serotonin receptor antagonist, NK-1 receptor antagonist
- Volunteers
- 300 people
- Sponsor
- Merck Sharp & Dohme LLC
Neoplasm Malignant
A Study of STRO-002 in Chinese Adults With Epithelial Ovarian Cancer and Other Advanced Malignant Solid Tumors
This is a multi-center, open-label, monotherapy dose escalation, PK bridging, and dose expansion Phase I/IIa study in Chinese adult subjects to evaluate the safety, tolerability, Pharmacokinetics (PK) profiles, immunogenicity…
- Trial name
- NCT06238687
- Testing
- STRO-002
- Where
- China
- Volunteers
- 19 people
- Sponsor
- Tasly Pharmaceutical Group Co., Ltd
Advanced Solid Tumors
A Phase Ib/II Clinical Study of AK127 in Combination With AK112 in Patients With Advanced Solid Tumors
A Phase Ib/II Open-label Clinical Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of AK127 in combination with AK112 in Patients with Advanced Malignant Tumors
- Trial name
- NCT05951608
- Testing
- AK127 in combination with AK112
- Where
- China
- Volunteers
- 216 people
- Sponsor
- Akeso
Advanced Solid Tumor
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
This study will evaluate the safety, efficacy, optimal dose, and pharmacokinetics (PK) of BNT326 as monotherapy (Part 1) and as combination treatment with immunotherapeutic agents (Part 2) in participants with histologically or…
- Trial name
- NCT07070232
- Testing
- BNT326, Pumitamig, Itraconazole
- Where
- 77 sites in United States, Australia and 7 more
- Volunteers
- 1,438 people
- Sponsor
- BioNTech SE
Advanced Malignant Solid Tumors
SCTB41 Plus SCTB39G With or Without Standard Therapy in Advanced Solid Tumors
This study aims to evaluate the safety, tolerability, PK characteristics, immunogenicity, and preliminary anti-tumor efficacy of SCTB41 in combination with SCTB39G with or without standard therapy in adult patients with advanced…
- Trial name
- NCT07665970
- Testing
- SCTB41+SCTB39G
- Volunteers
- 112 people
- Sponsor
- Sinocelltech Ltd.
Advanced Solid Tumor, Advanced Cancer
AMT-151 in Patients With Selected Advanced Solid Tumours
This first-in-human study will evaluate the Maximum Tolerated Dose (MTD) / the Recommended Phase 2 Dose (RP2D), safety, tolerability, anti-tumor activity, pharmacokinetics, pharmacodynamics and immunogenicity of AMT-151, a novel…
- Conditions
- Advanced Solid Tumor, Advanced Cancer, Advanced Carcinoma, Ovarian Cancer
- Trial name
- NCT05498597
- Testing
- AMT-151
- Where
- 9 sites in Australia, China
- Volunteers
- 30 people
- Sponsor
- Multitude Therapeutics Inc.
Malignant Neoplasms
A Study of IMMH-010 in Patients With Advanced Malignant Solid Tumors
Phase I study of IMMH-010 in patients with advanced malignant solid tumors
- Trial name
- NCT04343859
- Testing
- IMMH-010
- Where
- China
- Volunteers
- 96 people
- Sponsor
- Tianjin Chasesun Pharmaceutical Co., LTD